downgrad underweight
impella pressur continu appear structur
penetr deliv slower growth
higher spend drive reduct project
dcf valu downgrad underweight pt
tip point less construct sinc
downgrad equal-weight august see discuss
pressur begin look structur transient time impella
appear transit matur market outlook given
address market catalyst ecp btr stemi year away
see path acceler recent data public american
heart associ aha meet muddl water current
futur impella util see note earn survey see
suggest acut impact evidenc last week guidanc
wake yesterday jama public discuss
concern reach point compani sponsor random
control trial go critic addit penetr
specif recent survey physician commentari center need
robust data use impella appropri patient popul without
see secular growth rate lower invest drive forward sale
move higher combin factor drive number lower
reduc dcf valu admittedli expect low cash
flow provid downsid protect dont see clear path meaning
acceler intermedi term believ rel lag
coverag
jama chang debat larg observ studi aha
cast doubt mechan circulatori support outcom suggest
higher advers event name death bleed impella iabp
well increas hospit cost phd studi mean
clear found initi circul paper less compel data
contemporan arm trial poorli match
expect second data set paper publish major journal
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
yesterday jama public see discuss may repres
tip point compani dilig suggest jama like
disrupt referr channel given mainstream statu contrast
circul paper jama studi note rise impella use
acut mi cardiogen shock amic patient contain better
match control contemporan look
analys type limit exhibit exhibit clearli
demonstr jama robust studi better match result also
exhibit pronounc differ patient receiv pci
versu
pci group mortal impella user vs
iabp patient major bleed vs
pci group mortal impella vs iabp
wherea major bleed vs see exhibit
beyond circul jama late last week italian registri echo
similar concern note meaning rise impella use among cardiogen
shock high-risk pci patient averag annual increas
despit elev device-rel complic rate
respect studi also show in-hospit all-caus death one-
year cg patient respect
hr pci patient
told clear clinic commun begin ask harder question
around use impella appropri patient believ recent data go
increas scrutini impact current util futur adopt
guidanc low end growth rang confirm recent
pressur structur natur lower growth
assumpt
estim pt street intermedi term next year
compound-annual-growth-rate move also believ increas invest
requir next sever year stimul market growth particularli
area clinic trial market develop manag address
earn call lower earn expect
oper margin assumpt move lower
respect
chang drive reduct dcf-base per share
valu assumpt dcf includ wacc termin growth
rate termin oper margin updat price target reflect
downsid today share price downgrad underweight
rel basi dcf impli sale multipl sale
repres discount high growth smid cap comp set reflect
lower growth rate prior model
compound-annual-growth-rate versu peer set exhibit discuss insid
factor could impact thesi state earlier less
construct sinc middl last year structur concern
lost street near-term recoveri could temporari catalyst
share focu area roll-out addit studi pipelin
meaning revers sinc tct analyst day
will run random clinic trial high-risk pci cardiogen
shock patient protect iv see long-term posit
result studi avail
roll-out impella ecp fim expand sheath us
roll-out continu smartassist system upgrad on-going
reimburs updat april time-frame upcom analyst day
may focu catalyst model impella acceler model
see ecp import driver long-term
respect reimburs although propos posit
revis last sever year dilig suggest reimburs
like head lower time may overhang april
initi propos rate made public
abiom slowdown structur transient downgrad underweight
abiom slowdown structur transient downgrad underweight
price target support dcf assum
wacc termin growth impli multipl
base case sale high growth devic peer
assum sale grow driven continu impella
penetr protect pci shock
impella penetr take faster expect util increas
exist impella site driven new product launch increas data
expans effort organ growth sustain high teen
longer tail stemi repres meaning expans opportun
posit feasibl day multipl expand higher growth durabl longer
dcf analysi impli ev/sal
dcf analysi impli ev/sal
impella growth slow low-teen near intermedi term stemi still
repres meaning expans opportun posit feasibl
data ebit margin miss origin lrp surpass
multipl high growth peer lack competit
peer profit off-set structur slowdown pace
growth adopt curv matur
recent growth trend prove anomal impella sale growth deceler
singl digit multipl contract reflect slower growth profil potenti
market size disappoint and/or expans delay
growth slow seen prior
year teen y/i growth impella growth
slowdown becom structur
margin expans pace slow stand
origin lrp
reimburs could head lower
stemi pivot trial continu
repres key longer term expans
opportun market
sustain reimburs broader
pma approv rp launch ecp
broader commerci launch japan
us stemi impli
risk achiev price
risk pt includ faster
expect impella roll-out japan
expans ii revers trend prior
faster expect stemi expans
iv recent neg articl
impact procedur volum
quick comparison match characterist
comparison exhibit suggest patient cohort
better match two arm versu circul studi across
characterist age histori diabet multivessel diseas addit
variabl congest heart failur chronic renal failur atherectomi
nstemi also poorli match circul studi
abiom press releas nov select data publish circul studi
million except ep
sale
sale
sale
sale
end
end
closer look valuat
base case pt reflect ev sale multipl versu close
multipl embed prior pt contract multipl primarili
driven slow growth appear structur transient
lower growth estim compound-annual-growth-rate
accordingli rel growth orient smid expens growth
adjust basi impli multiple-to-growth ratio use sale multipl
compound-annual-growth-rate multipl percent compound-annual-growth-rate rel high
growth smid comp set ratio smid multipl percent compound-annual-growth-rate
said materi profit also look profit larg
cap growth compani trade roughli line
edward believ grow faster less substanti structur risk
materi expens upper end revenu
guidanc grow similarli
valuat methodolog risk associ recommend rate price target referenc report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
invest
st debt current portion lt debt
loss sale properti equip
net chang work capit
purchas invest
sale invest
net invest
chang equiti
effect exchang rate chang
net financ
begin year
end year
